Product Pipeline

Future Products

CYBIS

Pharmaceutical

  • Chronic Pain Formulation
  • THC + CBD + compounds
  • Clinical Development Programme
  • Administration: Oral solution
  • Full spectrum
  • Patient target: 2nd line therapy for chronic neuropathic pain.
CYM-001

CYM-001

Nutraceutical

  • Anxiety Formulation
  • CBD + specific formulated compounds
  • International ARTG registration and export
  • Administration: Oral solution
  • Full spectrum
  • Patient target: Highly Anxiolytic patients with pain.
cym-002-grey

CYM-002

Nutraceutical

  • Topical – pain
  • CBD + specifically formulated compounds
  • SAS Cat B

  • Administration: Oral solution

  • Patient target: Chronic neck and back pain

CYM-004

Pharmaceutical
(Contains THC)

  • Chronic Pain Formulation – 2nd generation
  • THC + CBD + compounds
  • Clinical Development Program based off our pre clinical research from UWS/NICM
  • Patient target: 2nd line therapy for chronic pain
cymra-icon

Cymra’s Pharmaceutical Experience and IP in regards to product and formulation development, clinical programs and regulatory pathways provides us a unique advantage over non pharmaceutical companies.

Note: All dates and products are provided as an estimate, supply times and products may vary.